RYTM
Rhythm Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -1.6% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | +7 | 44.38M | $4.90B | +14 | −8 |
| Q1 2026 | 109 | +6 | 41.83M | $3.64B | +11 | −6 |
| Q4 2025 | 102 | 0 | 43.14M | $4.62B | +3 | −2 |
| Q3 2025 | 20 | +1 | 28.88M | $2.92B | +2 | −2 |
| Q2 2025 | 17 | 0 | 22.96M | $1.45B | +1 | −1 |
| Q1 2025 | 14 | +2 | 11.52M | $610.22M | +2 | — |
| Q4 2024 | 12 | 0 | 11.40M | $638.39M | — | — |
| Q3 2024 | 11 | +3 | 9.71M | $508.75M | +3 | — |
| Q2 2024 | 8 | — | 9.56M | $392.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 6.27M | — | $396.05M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 2 | PRIMECAP Management ✦ | 4.88M | -15.7% | $308.24M | 0.2% | ▼ Trim | 5 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 3.59M | — | $226.80M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Fidelity (FMR) ✦ | 1.95M | — | $123.44M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 1.91M | -3.2% | $120.54M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.34M | +11.9% | $84.76M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Geode Capital Management ✦ (passive) | 1.31M | +1.9% | $82.87M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 376.24K | -29.7% | $23.77M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 9 | Adage Capital Partners ✦ | 341.00K | New | $21.55M | 0.0% | New | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 314.89K | +2131.4% | $19.90M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 207.39K | -7.2% | $13.10M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Millennium Management ✦ | 198.11K | -8.9% | $12.52M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 170.83K | +167.6% | $10.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 49.04K | +24.6% | $3.10M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 15 | D. E. Shaw & Co. ✦ | 24.28K | -71.0% | $1.53M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 16 | Wellington Management ✦ | 22.43K | -4.8% | $1.42M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 17 | Gotham Asset Management ✦ | 4.85K | +2.1% | $306,535 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $21.55M | 0.0% |
Exited
| Citadel Advisors | $3.71M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 284 holders, 72.02M shares, $6.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.82K sh · $189,965
Officer, Director · 8.70K sh · $899,634
Officer, Director · 30.75K sh · $3.15M
Officer, Director · 6.44K sh · $655,145
Officer, Director · 2.30K sh · $241,937
Officer · 11.51K sh · $1.21M
Officer · 23.07K sh · $2.41M
Officer · 28.19K sh · $2.99M
Officer · 2.01K sh · $233,031
Officer · 1.56K sh · $182,170
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology